Breast Neoplasms, Breast Cancer, Metastatic

Inclusion Criteria

- Female patients with a proven diagnosis of metastatic breast cancer 
 - Measurable disease as defined by the presence of at least one measurable lesion  
 - Patients must have received at least 3 weeks of continuous therapy with Taxane 
 -  patient must subsequently develop progressive disease either during treatment or within 6 months after treatment  
 - Patients who failed on hormone therapy   
 - Life expectancy of at least 12 weeks.  
 - Adequate bone marrow, liver and kidney function  
 - Patients with active brain metastases may be included

Exclusion Criteria

- Excluded medical conditions like: pre-existing neuropathy, active heart diseases or ischemia;  surgery within 4 weeks of study entry; serious infections; HIV infection; chronic hepatitis B or C; patients with brain metastases must be without a seizure; hypersensitivity to taxanes; organ transplants; some previous cancers 
  - Excluded therapies and medications, previous and concomitant such as: anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to study entry; more than two prior anticancer chemotherapy regimens; radiotherapy during study or within 4 weeks prior to study entry; bone marrow transplant 
  - Others: pregnant or breast-feeding patients; women enrolled in this trial must use adequate barrier birth control measures during the course of the trial; substance abuse, medical, psychological or social conditions that may interfere with the patient's participation.